Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Sight Sciences, Inc.NASDAQ: SGHT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 21.9% from a year ago
Cash & equivalents stood at $84.96M at the end of Q1 FY2026, down 21.9% from a year earlier and down 7.6% from the prior quarter. Over 3 fiscal years it compounded at -20.8% a year.
Context
- Cash & equivalents amounted to 77.4% of total assets at the end of Q1 FY2026, down 6.4 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -21.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 91.97M USD
- Year-over-year change
- -23.6%
- 4-year CAGR
- -22.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.97M | -23.6% |
| FY2024 | 2024-12-31 | 120.36M | -12.9% |
| FY2023 | 2023-12-31 | 138.13M | -25.3% |
| FY2022 | 2022-12-31 | 185M | -29.0% |
| FY2021 | 2021-12-31 | 260.69M | — |
Cash & Equivalents vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's Mar 2026 cash & equivalents of $84.96M is the lowest of the 7 companies compared; the peer median is $452.8M.
- Its year-over-year change of -21.9% is the lowest of 6, against a peer median of +13.9%.
- Cash & equivalents amounts to 77.4% of total assets for SGHT, versus a peer median of 17.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.83B | +5.7% | +32.9% | 7.4% | |
| Sep 2026 | $1.71B | +13.9% | +15.9% | 5.4% | |
| Mar 2026 | $666.7M | +90.7% | +93.1% | 91.0% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $238.9M | — | — | 92.5% |
| Jun 2026 | $114.49M | +13.6% | -8.8% | 12.4% | |
| Mar 2026 | $94.64M | +41.8% | -8.8% | 22.6% | |
| Mar 2026 | $84.96M | -21.9% | -20.8% | 77.4% | |
| Peer median (excluding SGHT) | $452.8M | +13.9% | +15.9% | 17.5% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 260.69M | 185M | 138.13M | 120.36M | 91.97M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 8.71M | 15.15M | 14.29M | 10.79M | 9.75M |
| Inventory | 3.48M | 6.11M | 7.85M | 6.33M | 7.77M |
| Other Current Assets | 1 | 3.42M | 2.6M | 2.31M | 3.26M |
| Total Current Assets | 277.04M | 209.68M | 162.87M | 139.77M | 112.73M |
| Property, Plant & Equipment (Net) | 2.95M | 3.19M | 3.1M | 2.52M | 2.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 202K | 211K | 682K | 550K | 518K |
| Total Non-current Assets | 3.15M | 3.4M | 3.78M | 3.07M | 2.57M |
| Total Assets | 280.19M | 213.07M | 166.65M | 142.84M | 115.3M |
| Account Payables | 3.35M | 2.69M | 1.73M | 1.69M | 1.34M |
| Short-term Debt | 0 | 0 | 2.22M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.99M | 7.35M | 4.53M | 9.68M | 6.07M |
| Total Current Liabilities | 13.5M | 17.82M | 12.25M | 15.47M | 11.03M |
| Long-term Debt | 32.66M | 33.31M | 31.71M | 39.36M | 40.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 879K | 1.23M | 1.56M | 19K | 31K |
| Total Non-current Liabilities | 34.58M | 35.18M | 34.18M | 39.85M | 40.33M |
| Total Liabilities | 48.08M | 53M | 46.44M | 55.32M | 51.36M |
| Common Stock | 48K | 48K | 49K | 51K | 54K |
| Retained Earnings | (153M) | (239.24M) | (294.79M) | (346.3M) | (384.72M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 232.11M | 160.08M | 120.22M | 87.52M | 63.94M |
| Total Debt | 34.21M | 34.98M | 35.41M | 40.36M | 40.78M |
| Net Debt | (226.48M) | (150.02M) | (102.72M) | (80M) | (51.19M) |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.